Numbers Flashcards
<p>PKU incidence</p>
<p>1:100,000</p>
<p>PKU and risk congenital heart defect</p>
<p>7-10%</p>
<p>Fetal Phe levels </p>
<p>1.25-2.5x more than maternal</p>
<p>Woman >40yo how many pregnancies unplanned?</p>
<p>20%</p>
<p>Percentage of TOP in women >40yo</p>
<p>28%</p>
<p>Background risk VTE in non-pregnant non-contraceptive users</p>
<p>2:10,000</p>
<p>% normal population with anti phospholipid antibodies </p>
<p>1-2%</p>
<p>% of those with recurrent thrombosis with APS</p>
<p>20%</p>
<p>% of those with recurrent miscarriage with APS</p>
<p>15%</p>
<p>Risk of female carrier BRCA 1 developing breast cancer <70</p>
<p>60-80%</p>
<p>Risk of female carrier of BRaC-2 developing breast ca <70</p>
<p>45-85%</p>
<p>Incidence ectopic UK</p>
<p>11:1000</p>
<p>Incidence perforation in OP hysteroscopy</p>
<p>0.002-1.7%</p>
<p>Incidence of perforation in hysteroscopic surgery</p>
<p>1.6%</p>
<p>Perforation in ERPC for PPH</p>
<p>5%</p>
<p>Perforation for PMB Ix</p>
<p>0.2-2%</p>
<p>Perforation in TOP</p>
<p>0.4-0.5%</p>
<p>Cure rate GTD/GTN</p>
<p>98-100%</p>
<p>Incidence GTD</p>
<p>1:714 live births</p>
<p>PCOS in reproductive age</p>
<p>10-18%</p>
<p>Metabolic syndrome in PCOS</p>
<p>33%</p>
<p>Sickle cell heterozygous (trait) in UK</p>
<p>240,000</p>
<p>Sickle cell disease UK</p>
<p>12,500</p>
<p>Lifetime prevalence of uterovaginal prolapse</p>
<p>30-50%</p>
Per cent of women who have had surgery for UV prolapse by 80yo
12%
VBAC success overall
72-75%
VBAC + prev vaginal delivery success
85-90%
Success of VBAC + prev CS for fetal malpresentation
84%
Success of VBAC if prev CS fetal distress
73%
Success of VBAC + prev cs for Labour dystocia
64%
Background risk VTE women in 1 yr
2:10,000
Risk VTE in CHC + ethinlyestradiol + levogernestrel/norgestimate/norethisterone
5-7:10,000
Risk of VTE in etonogestrel (ring) or norelgestromin (patch)
6-12: 10,000
Risk VTE with ethinylestradiol + gestodone/desogestrel/drosperinone
9-12:10,000
Conception rate after UPA (within 120hrs)
1.3%
Conception rate after LNG
2.2%
Women who have gonorrhiea and chlamydia co-infection
40%
UV prolapse lifetime prevalence
30-50%
Vaginal vault prolapse recurrence after uterosacral ligament suspension
5-12%
Recurrence rate of vaginal vault prolapse after sacrocolpopexy
3-5%
Rate of increased UI after VH
60% over 60yo
Dyspareunia after anterior repair
15%
Risks of sacrocolpopexy - mesh erosion - SBO - ileus - recurrence
10.5% 1.2% 0.3% 3-5%
Per cent of women in lifetime who will have surgery for ovarian mass
10%
Incidence of ovarian cyst in premenopausal being malignant
1:1000
Incidence of ovarian cyst being malignant in 50yo
3:1000
Per cent of TOA being malignant in postmenopausal
49%
Per cent with chronic pelvic pain after 1 episode 2 episodes 3 episodes Of PID/TOA
```12% 30% 67%
Per cent of women under 40 affected by POI
1%
Most common cause of premature ovarian insufficiency
Idiopathic 90% | Chromosomal, AI, infective and iatrogenic 10%
IVF - mild OHSS
33%
IVF - mod/severe OHSS
3-8%
Prevalence of POI
1:100
Main cause of POI
90% idiopathic
Sensitivity of amniocentesis for diagnosing fetal CMV?
60-70%
Percentage of clinically significant red cell autoantibodies in pregnancy
0.4%
Percentage of red cell autoantibodies in pregnancy
1.2%
Level of anti K to refer to fetal med
any
Level of anti D to refer to fetal med
>4
Level of anti C to refer to fetal med
>7.5
Level of anti E to refer to fetal med
When anti C detected
Aim of transfusion PCV for fetal anaemia
PCV 0.7-0.85
Aim of transfusion PCV for neonatal anaemia
PCV 0.5-0.6
Percentage of women with bipolar disorder, without family history, of developing postpartum pyschosis
1:4
Percentage of women with bipolar disorder, with family history, of developing postpartum pyschosis
1:2
Risk of congenital infection with recurrent CMV
1-2%
Risk of congenital infection with primary CMV
30-40%
What percentage of infants with congenital CMV infection are symptomatic?
10-15%
Maternal mortality in UK?
8.76 per 100,000
Percentage of twins in live births?
3%
Incidence of puerperal genital haematoma? | Requiring surgical intervention?
1:700 | 1:1000
Congenital malformations of women with epilepsy without AEDs
2.8%
Valproate and congenital malformations
10.7%
AED Polytherapy and congenital malformations
16%
Risk of congenital malformations if previously affected child
16.8%
Lamotrigine and congenital malformations
2%
Carbamazepine and congenital malformations
3.4%
Keppra and congenital malformations
0.7%
Phenobarbital and congenital malformations
4.9%
Phenytoin and congenital malformations
7.36%
Risk of seizure in labour with epilepsy
1-4%
Percentage of brachial plexus injury in shoulder dystocia
2.3-16%
Maximum dose of lidocaine + adrenaline
7ml/kg
Risk of future PIH if previous PIH
16-47%
Risk of PET if previous PIH
2-7%
Risk of PIH if previous PET
13-53%
Risk of PET if previous PET
16%
Risk of PET if previous severe PET/HELLP/eclampsia led to birth <34/40
25%
Risk of PET if previous eclampsia led to birth <28/40
55%
Risk RDS at 37/40 ELCS
11%
Risk RDS at 38/40 ELCS
8%
Risk RDS at 39/40 ELCS
1.5%
Steroids reduce RDS by what per cent?
44%
Risk of miscarriage with amniocentesis
0.11%
Risk of miscarriage with CVS
0.22%
Percentage of inconclusive cffDNA tests
1.9-6%
cffDNA sensitivity and specificity for T21
99.4%, 99.9%
cffDNA sensitivity and specificity for T18
97.7%, 99.9%
Female tubal sterilisation failure rate
0.85-1.85%
Incidence of adnexal masses in pregnancy The incidence of ovarian malignancy in pregnancy
0.19–8.8% | 1 in 1500–32 000 pregnancies
Hyperreactio luteinalis - percentage of maternal virilisation?
14-25%
Luteoma of pregnancy - percentage of maternal virilisation?
25-50% | 50% of these have risk of fetal virilisation if female
Risk of heterotopic pregnancy in assisted reproduction?
1-2%
Risk of torsion of >6cm dermoid cyst in pregnancy
27%
Percentage that malignant germ cell tumours account for in ovarian tumours in pregnancy?
38%
Prevalence of acute appendicitis in pregnancy?
1:1500
Percentage of adnexal masses that are simple ovarian cysts <5cm in pregnancy
76%
Incidence of ovarian torsion in pregnancy
1-5:1000
Risk of mid trimester losses after radical trachelectomy
7% vs 4% BG
Risk of preterm births after trachelectomy
30%
LBR after trachelectomy
62.8%
Peripartum seizure risk in epilepsy
1-4%
Percentage of women with vasomotor symptoms after menopause
70%
Risk additional breast cancer cases if using HRT (E+P) for 5 years
6 extra per 1000 | (BG 22-48:1000 over 7.5yrs)
Risk of radiation cystitis
26%
Risk of bowel fistulae after radiotherapy for cervical ca.
8%
Risk of bladder atony requiring ISC after radical hysterectomy
2-3%
Risk of bowel obstruction after radiotherapy for cervical cancer
14.5%
Dyspareunia post radiotherapy for cervical cancer
55%
Recurrence of abruption after 1 previous
4%
Recurrence after 2 previous abruptions
19-25%
Risk of malignant potential in lichen sclerosis
5%
Risk of malignant potential in lichen planus
3%
5yr survival of Stage 1 cervical ca
80%
5yr survival of Stage 2 cervical ca
50%
5yr survival of Stage 3 cervical ca
20%
5yr survival of Stage 2 cervical ca
7%
Percentage of bilateral dysgerminomas
10%
Percentage of raised CA125 in EOC
>80%
Percentage of HMB due to submucosal fibroids
15%
Pregnancy post endometrial ablation
0.7%
Percentage of reoperation after endometrial ablation
20-27%
Percentage of women having hysterectomy in 5 years after endometrial ablation
14-20%
Percentage of women with cyclical bleeding post subtotal hysterectomy
5%
Percentage of PCO in general population
20-33%
Percentage of anovulatory infertility due to PCOS
80-90%
Percentage of ovulation induction with clomiphene citrate
70-85%
Percentage of patients pregnant after 6 cycles of clomiphene citrate
60-70%
Risk of multiple pregnancy in clomiphene citrate ovulation induction
10%
Risk of multiple pregnancy in gonadotrophin ovulation induction
<5
Percentage of endometriosis in reproductive age
6-10%
Sensitivity and specificity of dyschezia and deep dyspareunia for deep infiltrating endometriosis
74.5% | 68.7%
Risk of premature ovarian failure in bilateral endometrioma cystectomies
2.4%
Lifetime risk of colon cancer in Lynch syndrome
50-80%
Lifetime risk of endometrial cancer in Lynch syndrome
40-60%
Lifetime risk of ovarian cancer in Lynch syndrome
10-12%
Risk of primary peritoneal malignancy in BRCA1/ BRCA2 with oophorectomy
1-6%
5yr survival for ovarian cancer Stage 1
92%
5yr survival for ovarian cancer Stage 2
55%
5yr survival for ovarian cancer Stage 3
22%
5yr survival for ovarian cancer Stage 4
6%
5yr survival for ovarian cancer overall
43%
5yr survival for endometrial cancer Stage 1
95%
5yr survival for endometrial cancer Stage 2
77%
5yr survival for endometrial cancer Stage 3
39%
5yr survival for endometrial cancer Stage 4
14%
5yr survival for endometrial cancer overall
84.4%
Prevalence of cerebral palsy in <28/40
110:1000 | 1:10
Prevalence of cerebral palsy between 28-31/40
43:1000
Prevalence of cerebral palsy between 32-36/40
6.75:1000
Prevalence of cerebral palsy in >36/40
1.35:1000
Percentage of cerebral palsy due to PTB
35%
Percentage of pregnant women with anaemia
38%
Percentage of women with HMB and iron deficiency anaemia | or with severe iron deficiency
27% | 60%
Percentage that an ectopic pregnancy with 1 previous CS is a scar pregnancy
6.1%
Risk of recurrence of CS scar
3.25-5%
5 year survival in recurrent cervical cancer
6-77%
Pelvic exenteration mortality rate
Up to 14%
Pelvic exenteration morbidity rate
33-75% | Serious 50%
5 year survival after pelvic exenteration
54% 87% of these survive 10yrs+ Higher success if >5yr disease free interval, R0 and no lymph node involvement
Risk of recurrent pregnancy loss in prothrombin gene mutation
81%
Percentage of maternal deaths with recognised mental health problem
16.8%
Risk to baby with homebirth in nullips
4:1000
Percentage of transfer of nullips from home to obs unit
45%
Percentage of bowel injuries diagnosed post diagnostic laparoscopy
15%
Percentage of bladder injuries diagnosed post diagnostic laparoscopy
50%
Percentage of ureteric injuries diagnosed post diagnostic laparoscopy
70%
Failure rate of lap. sterilisation
1:200
Rate of adhesion at umbilicus after midline laparotomy
50%
Rate of adhesion at umbilicus after low transverse incision
23%
TOG - rate of bladder injuries in laparoscopy
0.02-8.3%
% of fistula formation in laparoscopic bladder injury
5%
% laparoscopic ureteric injury % in LAVH % in DIE
1-2% 9-11% 38%
Laparoscopic ureteric injury - lower 1/3 - middle 1/3 - upper 1/3
50% 30% 18%
% unrecognised ureteric injuries resulting in a nephrectomy
25%
% of neuro morbidity in DCDA if 1 twin death?
1%
% of neuro morbidity in MCDA if 1 twin death
26%
% of death in DCDA if 1 twin death
4%
% of death in MCDA if 1 twin death
15%
% of laparotomy conversion for laparoscopic hysterectomy
0.83-7% 0. 83% for subtotal 2. 79% for total
% with adhesions after open gynae surgery
34.5%
TOG: % of perforations by fitting an IUD | % of these resulting in bowel injury
15% | 3-7%
Rate of hysterectomy following perforation from TOP
7:100,000
% uterine perforations affecting anterior wall
40%
% uterine perforations affecting cervix
36%
% uterine perforations affecting right lateral wall
21%
% uterine perforations by suction curette
51%
% uterine perforations by Hegar
24%
% uterine perforations by curette
16%
